WINTON GROUP Ltd bought a new stake in Iqvia Holdings Inc (NYSE:IQV) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 2,771 shares of the medical research company’s stock, valued at approximately $271,000.
A number of other institutional investors have also recently modified their holdings of IQV. Winslow Evans & Crocker Inc. purchased a new position in shares of Iqvia in the 4th quarter worth approximately $123,000. Valeo Financial Advisors LLC purchased a new position in shares of Iqvia in the 4th quarter worth approximately $170,000. IFP Advisors Inc purchased a new position in shares of Iqvia in the 4th quarter worth approximately $200,000. Livforsakringsbolaget Skandia Omsesidigt purchased a new position in shares of Iqvia in the 4th quarter worth approximately $209,000. Finally, Atria Investments LLC purchased a new position in Iqvia in the fourth quarter valued at approximately $218,000. 92.34% of the stock is owned by institutional investors and hedge funds.
In related news, Director Michael J. Evanisko sold 816 shares of the firm’s stock in a transaction that occurred on Monday, March 5th. The shares were sold at an average price of $100.00, for a total value of $81,600.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider James H. Erlinger III sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $100.00, for a total transaction of $1,000,000.00. The disclosure for this sale can be found here. Insiders have sold 21,712 shares of company stock valued at $2,176,034 in the last three months. 6.00% of the stock is owned by insiders.
IQV stock opened at $94.85 on Friday. Iqvia Holdings Inc has a 1 year low of $78.09 and a 1 year high of $110.67. The stock has a market capitalization of $20,166.79, a P/E ratio of 21.75, a P/E/G ratio of 1.40 and a beta of 0.63. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 1.21.
Iqvia (NYSE:IQV) last announced its earnings results on Wednesday, February 14th. The medical research company reported $1.32 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.34 by ($0.02). The business had revenue of $2.16 billion for the quarter, compared to the consensus estimate of $2.14 billion. Iqvia had a net margin of 13.44% and a return on equity of 13.03%. Iqvia’s revenue for the quarter was up 10.7% on a year-over-year basis. During the same period in the prior year, the business posted $1.09 EPS. equities analysts anticipate that Iqvia Holdings Inc will post 5.02 earnings per share for the current fiscal year.
IQV has been the topic of several research analyst reports. TheStreet upgraded Iqvia from a “c+” rating to a “b” rating in a research note on Wednesday, December 13th. Mitsubishi UFJ Financial Group initiated coverage on shares of Iqvia in a report on Friday, December 15th. They set a “neutral” rating and a $112.00 target price on the stock. Zacks Investment Research raised shares of Iqvia from a “hold” rating to a “buy” rating and set a $112.00 target price on the stock in a report on Thursday, January 18th. Evercore ISI began coverage on shares of Iqvia in a report on Thursday, January 18th. They issued an “outperform” rating and a $112.00 price target on the stock. Finally, SunTrust Banks reaffirmed a “hold” rating and issued a $110.00 price target on shares of Iqvia in a report on Monday, January 22nd. Eight equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $110.02.
ILLEGAL ACTIVITY WARNING: This article was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.dispatchtribunal.com/2018/04/07/2771-shares-in-iqvia-holdings-inc-iqv-purchased-by-winton-group-ltd.html.
Iqvia Company Profile
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.